Evidence map›Paper›PMID 36535987›Full record

ArticleNPJ vaccines2022

Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern.

Juan Shi, Gang Wang, Jian Zheng, Abhishek K Verma, Xiaoqing Guan, Moffat M Malisheni, Qibin Geng, Fang Li, Stanley Perlman, Lanying Du

Open access · goldAbstract read
In one paragraph

Article in NPJ vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Juan Shi *Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
Gang Wang *Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
Jian Zheng *Department of Microbiology and Immunology, University of Iowa, Iowa City, IA, USA.ORCID http://orcid.org/0000-0003-0909-128X
Abhishek K VermaDepartment of Microbiology and Immunology, University of Iowa, Iowa City, IA, USA.
Xiaoqing GuanInstitute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
Moffat M MalisheniInstitute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
Qibin GengDepartment of Pharmacology, University of Minnesota Medical School, Minneapolis, MN, USA.
Fang LiDepartment of Pharmacology, University of Minnesota Medical School, Minneapolis, MN, USA.ORCID http://orcid.org/0000-0002-1958-366X
Stanley PerlmanDepartment of Microbiology and Immunology, University of Iowa, Iowa City, IA, USA. stanley-perlman@uiowa.edu.ORCID http://orcid.org/0000-0003-4213-2354
Lanying DuInstitute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA. ldu3@gsu.edu.ORCID http://orcid.org/0000-0001-5955-1294
Georgia State University · USUniversity of Iowa · USUniversity of Minnesota · USUniversity of Minnesota Medical Center · US

Funding

Structure-based design of coronavirus subunit vaccinesR01AI139092 · NIAID · NEW YORK BLOOD CENTER · PI DU, LANYING · 2018 to 2022
$4.2M
Rational design and evaluation of novel mRNA vaccines against MERS-CoVR01AI137472 · NIAID · NEW YORK BLOOD CENTER · PI DU, LANYING · 2018 to 2022
$4.1M
Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronavirusesR01AI157975 · NIAID · NEW YORK BLOOD CENTER · PI DU, LANYING, LI, FANG · 2020 to 2025
$3.9M
NIAID NIH HHS R01 AI137472NIAID NIH HHS R01 AI139092NIAID NIH HHS R01 AI157975U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01AI137472U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01AI139092U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01AI157975
6 · The paper itself

Abstract

The SARS-CoV-2 Omicron variant harbors more than 30 mutations in its spike (S) protein. Circulating Omicron subvariants, particularly BA5 and other variants of concern (VOCs), show increased resistance to COVID-19 vaccines that target the original S protein, calling for an urgent need for effective vaccines to prevent multiple SARS-CoV-2 VOCs. Here, we evaluated the neutralizing activity and protection conferred by a BA1-S subunit vaccine when combined with or used as booster doses after, administration of wild-type S protein (WT-S). A WT-S/BA1-S cocktail, or WT-S prime and BA1-S boost, induced significantly higher neutralizing antibodies against pseudotyped Omicron BA1, BA2, BA2.12.1, and BA5 subvariants, and similar or higher neutralizing antibodies against the original SARS-CoV-2, than the WT-S protein alone. The WT-S/BA1-S cocktail also elicited higher or significantly higher neutralizing antibodies than the WT-S-prime-BA1-S boost, WT-S alone, or BA1-S alone against pseudotyped SARS-CoV-2 Alpha, Beta, Gamma, and Delta VOCs, and SARS-CoV, a closely related beta-coronavirus using the same receptor as SARS-CoV-2 for viral entry. By contrast, WT-S or BA1-S alone failed to induce potent neutralizing antibodies against all these viruses. Similar to the WT-S-prime-BA1-S boost, the WT-S/BA1-S cocktail completely protected mice against the lethal challenge of a Delta variant with negligible weight loss. Thus, we have identified an effective vaccination strategy that elicits potent, broadly, and durable neutralizing antibodies against circulating SARS-CoV-2 Omicron subvariants, other VOCs, original SARS-CoV-2, and SARS-CoV. These results will provide useful guidance for developing efficacious vaccines that inhibit current and future SARS-CoV-2 variants to control the COVID-19 pandemic.

Identifiers

PMID36535987
PMCPMC9762654
OpenAlexW4312113225

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.